Scope and Claims Analysis of US Patent 10,980,803: Long-Acting Aripiprazole IM Dosing by CYP2D6 Metabolizer and CYP Inhibitor Status

US Patent 10,980,803 is a US-method patent that narrows “what you must do” to treat schizophrenia using a long-acting, systemically released, intramuscular (IM) aripiprazole depot with dose adjustments tied to CYP2D6 metabolizer status and concomitant strong CYP3A4/CYP2D6 inhibitor use, plus anatomic injection site limitations (deltoid and gluteal sub-sites). Claim scope is driven by a fixed pharmacokinetic release period (“about one month”), a specific set of reduced aripiprazole dose amounts and prodrug dose amounts, and treatment logic that conditions dosing on enzyme function and inhibitor exposure duration (at least 14 days).

Because the claims are method-of-treatment with tightly specified dosing and patient CYP/inhibitor parameters, the practical infringement question is not “is there a long-acting aripiprazole product?” but “does the administered regimen match each claimed combination of: (1) drug form, (2) IM route, (3) approximate one-month release profile, (4) specified adjusted dose values (or specified prodrug amount), (5) metabolizer/inhibitor status, (6) inhibitor exposure window where required, and (7) specified injection muscle.”

What is US Patent 10,980,803 and what do its claims actually cover?

Core claim concept: prescribing a monthly IM long-acting aripiprazole regimen for schizophrenia with dose selection based on CYP2D6 phenotype (poor metabolizer vs extensive metabolizer) and whether the patient is taking strong CYP2D6 and/or CYP3A4 inhibitors, and selecting the injection muscle.

Claim 1 is the anchor and sets the baseline infringement theory:

Treat schizophrenia
IM administration of a long-acting suspension of adjusted-dose aripiprazole
Adjusted dose is about 300 mg aripiprazole or aripiprazole prodrug about 441 mg
Drug release is systemically released over about one month
Patient is a CYP2D6 poor metabolizer

From there, dependent claims narrow or vary:

injection site (deltoid or gluteal; ventrogluteal/dorsogluteal)
selection of prodrug chemical identity (Claim 4)
presence/absence of strong CYP inhibitors (Claims 5, 6, 9, 14, 19, 23)
initial recommended dose baseline (claims that state normal-enzyme initial recommended doses like 400 mg, 300 mg, 662 mg)
inhibitor duration threshold: at least 14 days (Claims 11, 15, 20, 24)
extensive metabolizer language in inhibitor-conditioned claims (Claims 10, 16)

How broad are the independent claims (especially Claim 1) and what are the limiting elements?

Claim 1 limitations (required elements for method infringement)

Disease/indication: treating schizophrenia.
Route and dosage form: IM administration of a long-acting suspension.
Drug identity: aripiprazole or an aripiprazole prodrug.
Dose range is value-based and specific: “about 300 mg” aripiprazole or about 441 mg** prodrug.
Pharmacokinetic timing: “systemically released over about one month.”
Patient phenotype criterion: CYP2D6 poor metabolizer.

Practical breadth consequence: even if a clinician uses IM long-acting aripiprazole for schizophrenia, the claim will not read unless the regimen matches the adjusted dose value(s) and the patient meets the CYP2D6 poor metabolizer criterion. Generic “dose adjustment” language does not appear; the claims are anchored on specific numeric doses plus the one-month release requirement.

Dependent claim structure and what it adds

Claim 2 adds injection muscle: deltoid or gluteal
Claim 3 further splits gluteal into ventrogluteal or dorsogluteal
Claim 4 defines the prodrug structure by chemical name (hardens the prodrug coverage)
Claim 5 adds a negative limitation: in the CYP2D6-poor metabolizer case, patient is not concomitantly administered strong CYP3A4 or strong CYP2D6 inhibitors
Claim 6 onward build parallel dosing profiles for different CYP inhibition configurations, including extensive metabolizers.

What specific dose adjustments and CYP criteria are claimed for aripiprazole and the prodrug?

Claim-by-claim dose/CYP mapping

Claim	IM long-acting aripiprazole regimen for schizophrenia	Adjusted dose / prodrug amount	CYP criterion stated	Concomitant inhibitor status	Inhibitor duration
1	IM long-acting suspension; ~1-month release	~300 mg aripiprazole or ~441 mg prodrug	CYP2D6 poor metabolizer	Strong CYP3A4 or strong CYP2D6 inhibitors: not specified in claim 1	Not specified
2-3	Adds injection site	Same as Claim 1	Same	Same	—
4	Prodrug specificity	Prodrug chemical name (7-(... ) dodecanoate)	Same	Same	—
5	Adds inhibitor exclusion	Same as Claim 1	CYP2D6 poor metabolizer	Not concomitantly administered strong CYP3A4 inhibitor or strong CYP2D6 inhibitor	—
6	IM long-acting suspension; ~1-month release	200 mg aripiprazole	CYP2D6 poor metabolizer	CYP3A4 inhibitor concomitantly	Not specified
7-8	Adds injection site	Same as Claim 6	Same	Same	—
9	IM long-acting suspension; ~1-month release	300 mg aripiprazole or 441 mg prodrug	Patient has strong CYP2D6 or CYP3A4 inhibitor use; includes “initial recommended dose” logic	Concomitant strong CYP2D6 or CYP3A4 inhibitors	Not specified
10	Adds metabolizer statement	Same as Claim 9	CYP2D6 and CYP3A4 extensive metabolizer	Strong inhibitor use still relevant due to claim 9	—
11	Adds inhibitor duration	Same as Claim 9	Extensive metabolizer (from claim 10)	Strong CYP2D6 or CYP3A4 inhibitors	≥ 14 days
12-13	Adds injection site	Same as Claim 9	Same	Same	—
14	IM long-acting suspension; ~1-month release	200 mg aripiprazole	Has concomitant CYP2D6 and CYP3A4 inhibitors	Both inhibitors concurrently	Not specified here
15	Adds inhibitor duration	Same as Claim 14	Has concomitant inhibitors	Both inhibitors concurrently	≥ 14 days
16	Adds metabolizer statement	Same as Claim 14	CYP2D6 and CYP3A4 extensive metabolizer	Both inhibitors concurrently	—
17-18	Adds injection site	Same as Claim 14	Same	Same	—
19	IM long-acting suspension; ~1-month release	198 mg aripiprazole	Strong CYP2D6 or CYP3A4 inhibitor use; includes “initial recommended dose” logic	Concomitant strong CYP2D6 or CYP3A4 inhibitor	—
20	Adds inhibitor duration	Same as Claim 19	Strong inhibitor configuration	Strong inhibitor	≥ 14 days
21-22	Adds injection site	Same as Claim 19	Same	Same	—
23	IM long-acting suspension; ~1-month release	159 mg aripiprazole	Concomitant CYP2D6 and CYP3A4 inhibitors; includes “initial recommended dose” logic	Both inhibitors concurrently	—
24	Adds inhibitor duration	Same as Claim 23	Concomitant inhibitors	Both inhibitors	≥ 14 days
25-26	Adds injection site	Same as Claim 23	Same	Same	—

What the numeric values do to infringement risk

The claims list discrete adjusted dose amounts rather than broad ranges. That increases the chance that design-arounds or labeling-driven regimens can avoid literal scope if they do not use the claimed “about X mg” values.

However, “about” creates some interpretive leeway, but it still tends to function as a bounded adjustment anchored to the stated numbers.

How do the injection-site limitations affect claim coverage?

Multiple dependent claims restrict the administration site:

Deltoid or gluteal muscle (Claim 2, 7, 12, 17, 21, 25)
Gluteal sub-sites:
- ventrogluteal and dorsogluteal (Claim 3, 8, 13, 18, 22, 26)

Scope impact:

If a regimen is identical in all other respects but delivered in a non-claimed muscle location, it may avoid infringement of those dependent claims.
Independent Claim 1 does not require site, so administration location can still matter via dependent claims, not via the broadest claim.

What is claimed about the aripiprazole prodrug and does that narrow the patent landscape?

Claim 4 identifies the prodrug by chemical name:

“7-(4-(4-(2,3-dichlorophenyl)piperazin-1-yl)butoxy)-2-oxo-3,4-dihydroquinolin-1(2H)-yl)methyl dodecanoate.”

Landscape consequence:

Coverage for the prodrug path depends on whether the competitor’s “prodrug” is the same chemical entity.
If competitors use a different prodrug or different prodrug moiety, Claim 4 may not read, even if the dose number and IM one-month release profile match.

What do the inhibitor-conditioned claims require, including the “at least 14 days” element?

Several claims add an exposure-duration requirement:

Claim 11: strong CYP2D6 or CYP3A4 inhibitors for at least 14 days
Claim 15: CYP2D6 + CYP3A4 inhibitors for at least 14 days
Claim 20: strong CYP2D6 or CYP3A4 inhibitor for at least 14 days
Claim 24: CYP2D6 + CYP3A4 inhibitors for at least 14 days

Scope consequence:

For literal infringement, evidence must support that the patient had concomitant inhibitor use meeting the ≥14-day time threshold before or during the treatment regimen described.
If a regimen is started with a shorter inhibitor window, it may avoid those specific dependent claims.

Is the patent directed to a specific commercial aripiprazole product or a class?

The claims are drafted as:

a long-acting suspension with ~one-month systemic release
IM administration
aripiprazole at specific adjusted doses or an aripiprazole prodrug at a specific adjusted dose
patient stratification by CYP2D6 phenotype and CYP inhibitor presence/duration
schizophrenia treatment

The claim set does not cite a product name in the text provided, but the structure of the regimen aligns with monthly IM aripiprazole long-acting formulations and their prodrug alternative dosing logic.

Operational implication for patent landscape: the patent is likely to be asserted against companies marketing long-acting aripiprazole regimens (or providing dosing instructions) that follow the claimed CYP/inhibitor-adjusted dosing and injection site parameters.

How to read the claim set for “design-around” opportunities

1) Dose value and “about”

If competitor dosing protocols use different adjusted doses that do not fall within “about 300 mg,” “about 200 mg,” “about 198 mg,” or “about 159 mg,” it can reduce literal infringement risk.
If dosing aligns with different label adjustments based on inhibitor phenotypes, it can also avoid the exact numeric trigger values.

2) Phenotype vs inhibitor status logic

Claim 1 and Claim 5 are tied to CYP2D6 poor metabolizer and (in Claim 5) explicitly exclude concomitant strong CYP3A4/CYP2D6 inhibitors.
Claims 6, 9, 14, 19, 23 shift the criterion to combinations that include strong CYP inhibitor presence and sometimes extensive metabolizer statements.

3) Inhibitor duration

Claims with “at least 14 days” introduce time-based carving.
Regimens that rely on short-term inhibitor coadministration could avoid those dependent claims.

4) Injection site

Deltoid and gluteal limits create a potential procedural design-around if administration uses an unclaimed muscle route.

5) Prodrug identity

If only an aripiprazole parent compound is used, prodrug-specific claims are avoided.
If a different prodrug is used, Claim 4’s chemical specificity may not apply.

What is missing for a complete US patent landscape report on 10,980,803?

A full Bloomberg-style “landscape” requires the patent bibliographic data and the rest of the family (publication numbers, priority dates, assignees, continuations/divisionals, claim set context, and related Orange Book entries) and litigation/ANDA/BLA events. The prompt only provides the asserted claim text and not the patent’s bibliographic record. Without that record, a complete, accurate assessment of:

claim breadth versus the specification’s description
priority dates and family member expirations
prosecution history (limiting statements, narrowing amendments)
whether the patent is listed in the FDA Orange Book for any specific NDA with the long-acting aripiprazole products
whether there are related continuation patents that overlap on CYP/dose/injection site variables
which companies filed Paragraph IV certifications or are in case law tied to this exact number

cannot be completed.

Key Takeaways

US 10,980,803 is a method-of-treatment patent that requires IM long-acting aripiprazole (or a specific aripiprazole prodrug) with ~one-month systemic release for schizophrenia.
The claims are narrowed by numeric adjusted dose values (not generic titration) and by patient CYP2D6 phenotype and strong CYP2D6/CYP3A4 inhibitor status, including a ≥14-day inhibitor duration in multiple dependent claims.
Injection site (deltoid, ventrogluteal, dorsogluteal) matters through dependent claims.
Prodrug coverage is chemically specific via Claim 4’s defined aripiprazole prodrug structure.
Practical infringement hinges on whether an accused regimen matches the full combination of drug form, dosing amount, one-month release, CYP/inhibitor criteria, timing threshold where required, and injection muscle limitations.

FAQs

1) Does US 10,980,803 cover any long-acting aripiprazole IM treatment, or only monthly one-month release suspensions?
It requires a long-acting suspension with systemic release over about one month, so regimens not meeting that release profile fall outside the claim language.

2) If a clinician treats schizophrenia with IM aripiprazole but doesn’t document CYP2D6 phenotype, does the claim still apply?
The claims require the patient is a CYP2D6 poor metabolizer or meets specified extensive/extensive metabolizer and inhibitor status conditions, so phenotype determination is embedded in the claim.

3) Do the claims require the patient to be on strong CYP inhibitors for at least 14 days?
Only in the dependent claims that include the “at least 14 days” limitation.

4) Is the prodrug covered only when it matches the specific chemical name in Claim 4?
Yes. Claim 4 narrows the prodrug option to the specifically named aripiprazole prodrug.

5) Can changing the injection site avoid infringement?
Injection site limitations appear in dependent claims, so avoiding deltoid/gluteal (ventrogluteal/dorsogluteal) can reduce risk for those dependent claims, while independent coverage still may exist.

References

US Patent 10,980,803 (claims provided in prompt).

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-001	Feb 28, 2013		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA, WITH EFFICACY IN TREATING ACUTE EPISODES OF SCHIZOPHRENIA	⤷ Start Trial
Otsuka Pharm Co Ltd	ABILIFY MAINTENA KIT	aripiprazole	FOR SUSPENSION, EXTENDED RELEASE;INTRAMUSCULAR	202971-003	Sep 29, 2014		RX	Yes	No	10,980,803	⤷ Start Trial				TREATMENT OF SCHIZOPHRENIA	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Details for Patent: 10,980,803

Which drugs does patent 10,980,803 protect, and when does it expire?

Summary for Patent: 10,980,803